title: Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan.
abstract: OBJECTIVE
  The aim of present study was to investigate the cytoprotective effect of amifostine on salivary glands in 131I-treated differentiated thyroid cancer (DTC) patients using serial quantitative analysis of salivary gland scans.
  
  
  METHODS
  Serial quantitative salivary scintigraphies were performed in 80 newly diagnosed DTC patients (9 men, 71 women; mean age, 43.2 years old; range, 21-58 years old). Forty-two patients were assigned randomly to the amifostine treatment group, which received 300 mg/m2 amifostine intravenously before 131I administration.
  
  
  RESULTS
  In both amifostine-treated and nontreated groups statistically significant declines of functional parameters after 131I treatment were revealed by quantitative salivary scintigraphy in DTC patients. Amifostine pretreatment did not prevent the parenchymal damage to major salivary gland function after 131I treatment (F = 1.37, p = 0.2461). However, the dose of 131I had significant effects on salivary gland function after 131I treatment (F = 9.72, p = 0.0002).
  
  
  CONCLUSIONS
  The present study did not show cytoprotective effects of amifostine for DTC patients treated with 131I.
authors.affiliation: Department of Nuclear Medicine, Pusan National University Hospital, Busan, Republic of Korea.
authors.forename: Seong-Jang
authors.initials: SJ
authors.lastname: Kim
authors.forename: Hee Young
authors.initials: HY
authors.lastname: Choi
authors.forename: In-Ju
authors.initials: IJ
authors.lastname: Kim
authors.forename: Yong-Ki
authors.initials: YK
authors.lastname: Kim
authors.forename: Sungmin
authors.initials: S
authors.lastname: Jun
authors.forename: Hyun Yul
authors.initials: HY
authors.lastname: Nam
authors.forename: Ju Sung
authors.initials: JS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D004999:Amifostine / Q000008:administration & dosage*; D002454:Cell Differentiation; D003131:Combined Modality Therapy; D019610:Cytoprotection; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011832:Radiation Injuries / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000008:administration & dosage*; D012469:Salivary Glands / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D007457:Iodine Radioisotopes; D011837:Radiation-Protective Agents; D004999:Amifostine